Swiss pharma giant Roche Holding AG’s (RHHBY) first-quarter 2024 revenues declined 6 % to CHF 14.4 billion due to the appreciation of the Swiss franc against most currencies and lower COVID-19-related sales. Nevertheless, sales were up 2% at constant exchange rates (CER) as demand for newer drugs as well as diagnostics products, including immunodiagnostics, clinical chemistry tests and advanced staining solutions, more than offset the anticipated decline in COVID-19-related sales and the impact of biosimila ...

A logo at the Roche Holding AG headquarters in Basel, Switzerland, on Thursday, Feb. 1, 2024.Swiss pharmaceutical company Roche on Wednesday reported a modest uptick in first-quarter sales, even as waning demand for its Covid-19 products continued to weigh on the company.Sales were up 2% at constant exchange rates, led by stronger demand for Roche's newer medicines and diagnostics, the company said. Excluding Covid-19 products, sales were up 7%. But sales tightened when reported in the company's local curre ...

Roche (RHHBY) announced that the FDA has approved a label expansion of its lung cancer drug, Alecensa.The drug is now approved for adjuvant treatment following tumor resection for patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) (tumors ≥ 4 cm or node-positive), as detected by an FDA-approved test.Alecensa is a kinase inhibitor, already approved as the first and second-line treatment for ALK-positive metastatic NSCLC, in various countries like the United States, Eur ...

Roche Holding AG (RHHBY) announced that the late-stage study evaluating its marketed drug, Columvi (glofitamab), in combination with gemcitabine and oxaliplatin (GemOx), for the treatment of relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) met its primary endpoint of overall survival.Columvi is Roche’s fixed-duration and CD20xCD3 T-cell engaging bispecific antibody. It is currently approved as a monotherapy by the FDA to treat people with R/R DLBCL after two or more lines of systemic thera ...

Roche's new Alzheimer's test has a long road ahead of it, but it may help boost the pharmaceutical company's slow growth rate.Shares of Swiss pharmaceuticals giant Roche Holdings (RHHBY 1.21%) stock popped 2.5% in early trading Thursday before giving back about half of its gains.Roche announced this morning that the U.S. Food and Drug Administration has awarded the "Breakthrough Device Designation" to its new Elecsys pTau217 plasma biomarker test for identifying amyloid pathology, a key feature of Alzheimer ...

Roche (RHHBY) has unveiled its latest innovation in diabetes care, paving its way into the continuous glucose monitoring (CGM) market, at the 17th International Conference on Advanced Technologies and Treatments for Diabetes in Florence, Italy. The new Accu-Chek SmartGuide solution for real-time CGM promises to revolutionize diabetes management with its predictive artificial intelligence (AI) capabilities, addressing critical unmet needs faced by individuals with diabetes.Roche is currently working toward o ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today data from Stage 1 of the National Institutes of Health (NIH)-sponsored pivotal Phase III OUtMATCH study evaluating the efficacy and safety of Xolair® (omalizumab) in patients allergic to peanuts and at least two other common foods were published in the New England Journal of Medicine (NEJM) and featured in a late-breaking symposium at the 2024 American Academy of Allergy, Asthma ...

Roche (RHHBY) announced that the FDA has approved a label expansion of the asthma drug Xolair (omalizumab).The regulatory body approved the drug for the reduction of allergic reactions, including anaphylaxis, that may occur with accidental exposure to one or more foods in adult and pediatric patients aged one year and older with IgE-mediated food allergy.The FDA approval is based on positive data from the late-stage OUtMATCH study, which evaluated Xolair in patients aged between one and 55 years who are all ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved Xolair® (omalizumab) for the reduction of allergic reactions, including anaphylaxis, that may occur with accidental exposure to one or more foods in adult and pediatric patients aged 1 year and older with IgE-mediated food allergy. People taking Xolair for food allergies should continue to avoid all foods they are all ...

Cristina Arias/Cover via Getty Images Description The Swiss company Roche (OTCQX:RHHBY) (OTCQX:RHHBF) (OTCPK:RHHVF) is one of the most well-recognized brands in the pharmaceutical sector. It has a CHF 187 billion market capitalization and annual revenues of CHF 58.7 billion (2023 data). With a 2.7% weight, it is the tenth largest company by weight within the MSCI world healthcare index. msci world health care sector weight (MSCI World) The company has a strong international presence, as it generates 48% of ...